SPC
NKTR icon

Sigma Planning Corp’s Nektar Therapeutics NKTR Stock Holding History

Sigma Planning Corp’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,000
Closed -$381K – 1376
2025
Q4 		$381K Buy
+9,000
New +$504K 0.01% 915
2018
Q4 		– Sell
-447
Closed -$409K – 930
2018
Q3 		$409K Buy
447
+28
+7% +$23.9K 0.02% 559
2018
Q2 		$307K Buy
+419
New +$483K 0.02% 640

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sigma Planning Corp's NKTR Position: Q1 2026 in Review

Sigma Planning Corp sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 9,000 shares — an estimated $381K sold.

Sigma Planning Corp first reported a position in NKTR in Q2 2018 and held it in 3 quarters. The position peaked at $409K in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Sigma Planning Corp reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sigma Planning Corp sold 9,000 Nektar Therapeutics shares in Q1 2026, an estimated $381K.
  • Sigma Planning Corp first reported a position in Nektar Therapeutics in Q2 2018 and held it in 3 quarters.
  • Sigma Planning Corp's Nektar Therapeutics position peaked at $409K in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.